Catalent (NYSE:CTLT) Upgraded by StockNews.com to Hold Rating

StockNews.com upgraded shares of Catalent (NYSE:CTLT) from a sell rating to a hold rating in a research note released on Thursday.

CTLT has been the topic of several other research reports. Robert W. Baird reissued a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Eight equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $63.40.

Catalent Stock Performance

Shares of Catalent stock opened at $59.10 on Thursday. The company’s 50 day moving average price is $59.84 and its two-hundred day moving average price is $58.21. The firm has a market capitalization of $10.73 billion, a P/E ratio of -26.15, a P/E/G ratio of 2.35 and a beta of 1.16. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. Catalent has a fifty-two week low of $36.74 and a fifty-two week high of $61.20.

Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.10) EPS. On average, equities analysts forecast that Catalent will post 0.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Catalent news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,114 shares of company stock worth $305,931. Corporate insiders own 0.31% of the company’s stock.

Institutional Trading of Catalent

Hedge funds have recently bought and sold shares of the business. Brooklyn Investment Group bought a new position in shares of Catalent in the third quarter valued at $31,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalent in the 2nd quarter valued at about $42,000. Sentry Investment Management LLC acquired a new position in Catalent during the 3rd quarter valued at about $53,000. Longfellow Investment Management Co. LLC increased its holdings in Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.